RPS6KA1 and melanoma: While our study reveals a marked heterogeneity in the pro-inflammatory response to RSK/PLK1 inhibitors in nine human melanoma cell lines (Fig 1D), most of our experiments compare only two cell lines, MeWo and A-375.